Page last updated: 2024-11-05

mestanolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mestanolone: non-virilizing androgenic steroid; RN given refers to (5alpha,17beta)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10633
CHEMBL ID261514
CHEBI ID31825
SCHEMBL ID146678
MeSH IDM0052166

Synonyms (96)

Synonym
AC-16142
mestanolonum
mestanolona
4-08-00-00656 (beilstein handbook reference)
s712yz168e ,
unii-s712yz168e
5alpha-androstan-3-one, 17beta-hydroxy-17-methyl-
ru 143
5-alpha-androstane-17-alpha-methyl-17-beta-ol-3-one
mestanolonum [inn-latin]
einecs 208-302-6
17alpha-methylandrostan-3-on-17beta-ol
17-alpha-methyldihydrotestosterone
mestanolone [inn:ban:jan]
17alpha-methyldihydrotestosterone
17-beta-hydroxy-17-methyl-5-alpha-androstan-3-one
5-alpha-androstan-3-one, 17-beta-hydroxy-17-methyl-
androstan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)-
17beta-hydroxy-17-methyl-5alpha-androstan-3-one
mestanolona [inn-spanish]
androstan-3-one, 17-hydroxy-17-methyl-, (5alpha,17beta)-
17alpha-methyl-5alpha-dihydrotestosterone
17alpha-methyl-5alpha-androstan-17beta-ol-3-one
17alpha-methylandrostanolone
17beta-hydroxy-17alpha-methyl-3-androstanone
nsc 18219
5alpha-androstane-17alpha-methyl-17beta-ol-3-one
17alpha-methyl-17beta-hydroxy-5alpha-androstan-3-one
brn 3207223
17beta-hydroxy-17alpha-methyl-5alpha-androstan-3-one
LMST02020027
17beta-hydroxy-17-methyl-androstan-3-one
methybol
17-methyldihydrotestosterone
assimil
mestalone
methylantalon
nsc-18219
5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl-
andoron
17.beta.-hydroxy-17-methyl-5.alpha.-androstan-3-one
5.alpha.-androstane-17.alpha.-methyl-17.beta.-ol-3-one
preroide
tantarone
mestanolone
methyldihydrotestosterone
17.alpha.-methyl-17.beta.-hydroxy-5.alpha.-androstan-3-one
mesanolon
ermalone
nsc18219
17.alpha.-methyldihydrotestosterone
17.alpha.-methyl-5.alpha.-dihydrotestosterone
MLS000759515
smr000238198
cpd000238198
mesanolon (tn)
mestanolone (jan/inn)
D01533
HMS2051M18
CHEMBL261514
(5s,8r,9s,10s,13s,14s,17s)-17-hydroxy-10,13,17-trimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-3-one
NCGC00183127-01
dtxsid0048973 ,
dtxcid3028899
tox21_113424
cas-521-11-9
MLS001424090
CCG-100893
AKOS015895448
17.alpha.-methylandrostan-17.beta.-ol-3-one
mestanolone [mi]
mestanolone [jan]
17.beta.-hydroxy-17.alpha.-methyl-3-androstanone
17.alpha.-methylandrostan-3-on-17.beta.-ol
mestanolone [mart.]
stanozolol impurity a [ep impurity]
(5.alpha.,17.beta.)-17-hydroxy-17-methylandrostan-3-one
mestanolone [who-dd]
mestanolone [inn]
bdbm50423547
SCHEMBL146678
NC00143
HY-B1903
CS-5233
W-105853
androstan-3-one, 17-hydroxy-17-methyl-, (5a,17b)-
CHEBI:31825
17alpha-methylandrostan-17beta-ol-3-one, analytical standard
stanozolol impurity a, european pharmacopoeia (ep) reference standard
17b-hydroxy-17a-methyl-5a-androstan-3-one
(5s,8r,10s,13s,17s)-17-hydroxy-10,13,17-trimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one
BCP10775
Q1924446
(5s,8r,9s,10s,13s,14s,17s)-17-hydroxy-10,13,17-trimethylhexadecahydro-3h-cyclopenta[a]phenanthren-3-one
mestanolone 100 microg/ml in methanol
(5alpha,17beta)-17-hydroxy-17-methylandrostan-3-one

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"17 alpha-Methyl-5 beta-androstane-3 alpha,17 beta-diol together with the hydroxylated metabolites 17 alpha-methyl-5 beta-androstane-1 beta,3 alpha,17 beta-triol, 17 alpha-methyl-5 beta-androstane-3 alpha,12 beta,17 beta-triol, 17 alpha-methyl-5 beta-androstane-3 alpha,16 alpha,17 beta-triol and 17 alpha-methyl-5 beta-androstane-3 alpha,16 beta,17 beta-triol were isolated and identified in the urine of rabbits orally dosed with 17 alpha-methyl-5 beta-dihydrotestosterone."( Metabolism of 17 alpha-methyl-5 beta-dihydrotestosterone in the rabbit.
Jackson, CC; Templeton, JF, 1983
)
0.27
" The resultant AD50 dosage levels (dosage at which 50% of the genotypic females were sex-reversed into phenotypic males) after a single 2-hr immersion treatment were: 30, 60, and 500 micrograms/liter for MDHT, MT, and 11-KT, respectively."( Effects of natural, synthetic, aromatizable, and nonaromatizable androgens in inducing male sex differentiation in genotypic female chinook salmon (Oncorhynchus tshawytscha).
Baker, IJ; Donaldson, EM; Piferrer, F, 1993
)
0.29
" The urinary concentrations of these metabolites after dosing were determined by GC/MS."( Identification and quantification of metabolites common to 17alpha-methyltestosterone and mestanolone in horse urine.
Aramaki, S; Hosoe, T; Kijima-Suda, I; Kurosawa, M; Nakazawa, H; Okayasu, T; Saito, K; Yamada, M, 2007
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
3-oxo-5alpha-steroidA 3-oxo steroid that has alpha configuration at position 5.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency0.00440.000221.22318,912.5098AID743036; AID743040; AID743053
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency8.48520.000214.376460.0339AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.92920.000229.305416,493.5996AID743069; AID743075; AID743077; AID743078; AID743079; AID743080
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.00210.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency6.68240.000323.4451159.6830AID743065; AID743067
DNA polymerase betaHomo sapiens (human)Potency79.43280.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency3.54810.039816.784239.8107AID1454
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sex hormone-binding globulinHomo sapiens (human)Kd0.00150.00020.34964.7863AID318680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID404838Androgenic activity in rat assessed as inverse logarithm of amount of enlargement of ventral prostate2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues.
AID404840Ratio of anabolic activity in rat levator ani muscle to androgenic activity in rat seminal vesicle2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues.
AID404837Anabolic activity in rat assessed as inverse logarithm of amount of increase in levator ani muscle weight2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID404839Androgenic activity in rat assessed as inverse logarithm of amount of enlargement of seminal vesicle2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues.
AID404841Lipophilicity, log P of the compound2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (24.39)18.7374
1990's12 (29.27)18.2507
2000's11 (26.83)29.6817
2010's6 (14.63)24.3611
2020's2 (4.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.92 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]